During the past decade, Onkologische Schwerpunktpraxis Kurfürstendamm conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 11 clinical trials were completed, i.e. on average, 52.4% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 7 clinical trials were completed. i.e. 58.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis Kurfürstendamm" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "German CLL Study Group" with 3 trials sponsored, "Institut de Recherches Internationales Servier" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Taiho Oncology, Inc." with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis Kurfürstendamm" #1 collaborator was "ADIR, a Servier Group company" with 2 trials as a collaborator, "Cancer Trials Ireland" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "Nordic CLL Study Group (NCLLSG)" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Onkologische Schwerpunktpraxis Kurfürstendamm" are "Breast Cancer" (5 trials), "Metastatic Colorectal Cancer" (4 trials), "Chronic Lymphoid Leukemia" (2 trials), "Colorectal Cancer" (2 trials) and "Non-Hodgkin's Lymphoma" (2 trials). Many other conditions were trialed in "Onkologische Schwerpunktpraxis Kurfürstendamm" in a lesser frequency.

Most popular intervention types in "Onkologische Schwerpunktpraxis Kurfürstendamm" are "Drug" (24 trials), "Biological" (5 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (5 trials), "Placebo" (5 trials), "Bevacizumab" (3 trials), "Cetuximab" (3 trials) and "Doxorubicin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Onkologische Schwerpunktpraxis Kurfürstendamm" are 27 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Onkologische Schwerpunktpraxis Kurfürstendamm". undefined are not yet recruiting, 9 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Onkologische Schwerpunktpraxis Kurfürstendamm, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Onkologische Schwerpunktpraxis Kurfürstendamm, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".